Toctino®

Toctino® (alitretinoin) is marketed in Austria, Canada, Denmark, Finland, France, Germany, Italy, Norway, Switzerland and the United Kingdom. In addition, the drug is approved in 17 further European countries as well as Israel. Basilea has appointed distributors for Toctino® in selected European markets, Canada, Israel, Mexico and the Republic of Korea. Furthermore, a phase III clinical trial on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S.